Lifecycle Management
Post-Market & Real-World Evidence
After approval, programs shift from trial control to real-world complexity. Biology meets daily practice. Algorithms evolve. Evidence must now adapt to real patients and real settings. This stage demands continuous learning.
What companies need at this stage
Teams need real-world biomarker validation, ongoing model refinement, and pipelines that can accomodate new data without losing traceability.
BioLizard solutions
- Continuous AI model retraining with updated clinical inputs.
- Real-world evidence integration with omics data.
- Diagnostic and algorithm refinement using multi-modal signals.
- Cloud architectures built for commercial scale.
Relevant Bio|Verse® modules
Bio|Verse® supports continuous learning loops, audit trails, and modular updates without disruptingproduction systems.
Explore →
Modular offerings
RWE integration packages | Diagnostic refinement modules | Ongoing model monitoring | Cloud maintenance and pipeline evolution
Explore all solutions →
Converting genetic resistance into metabolic yield
Salmonella infection in poultry has a detrimental effect on growth and therefore production. Knowledge of host resistance genes helps optimize precision management.
Omics-driven diagnostics in animals
Chronic diseases are a burden for companion animals, but can be managed better if diagnosed early. Multi-omics analysis is complex, but offers opportunities to discover novel biomarker panels.
Exploring target expression and identifying other indications with a similar mode of action
The client wanted to study the expression of their target gene within two known indications and to uncover other diseases where the target has a similar mode of action. Identifying comparable indications could strengthen the business case for further development. Our...